EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors

Jared Weddell iD

CPT: Pharmacometrics & Systems Pharmacology · 2023-11 · 12 (11) · 1726-1737

DOI: 10.1002/psp4.12928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 09.02.2023. Verfasst von Jared Weddell. Beteiligte Einrichtung: Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., Northbrook, Illinois, USA. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies exhibit proven clinical benefit, and many bispecifics are currently in clinical development for oncology. Cytokine release syndrome (CRS) is a common clinical adverse effect observed following CD3‐based bispecific dosing. However, the pathophysiology of CRS is not fully understood, and no computational model mechanistically describing clinical cytokine dynamics following bispecific dosing in solid tumors exists. Here, a quantitative systems pharmacology (QSP) model describing peripheral clinical cytokine dynamics following bispecific dosing in solid tumors is presented. Using tebentafusp as a case study, a CD3‐bispecific approved for uveal melanoma, the model successfully captures the dynamics of five cytokines. The QSP model was shown to predict observed phenomena, such as cytokine maximum concentration suppression using step‐up dosing regimens and the importance of on‐target off‐tumor binding toward CRS and toxicity. Furthermore, the QSP model provides rationale for these biological phenomena based on dynamics of immune cell activation and desensitization in tumors and healthy tissues. Overall, the QSP model structure presented here serves as a basis to infer cytokine dynamics for other CD3‐based bispecifics or tumor types by altering model parameters to capture the scenario of interest, supporting applications including dose selection, candidate nomination, and disease area selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntibodies, BispecificHumansCytokines

Substanzen

CytokinesAntibodies, Bispecific

Autor:innen und Institutionen

  • Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.

ORCID-Profile: Jared Weddell

Zitieren

APA

Weddell, J. (2023). Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT: Pharmacometrics & Systems Pharmacology, 12(11), 1726-1737. https://doi.org/10.1002/psp4.12928

Vancouver

Weddell J. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(11):1726-1737. doi:10.1002/psp4.12928

BibTeX
@article{Weddell2023,
  author = {Weddell, Jared},
  title = {Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  volume = {12},
  number = {11},
  pages = {1726--1737},
  doi = {10.1002/psp4.12928}
}
Kostenlos starten →